Nivolumab for the treatment of hepatocellular carcinoma

PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene

(2018) Kristin Nicole Berger et al.   GENE

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

(2018) Margaret K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma

(2018) R A Hlady et al.   HEPATOLOGY

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

(2017) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

(2017) Austin G. Duffy et al.   JOURNAL OF HEPATOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

(2017) Petros Fessas et al.   SEMINARS IN ONCOLOGY

Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?

(2016) Joerg Trojan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE